Commission Implementing Regulation (EU) 2026/372 of 20 February 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 1-naphthylacetamide, 1-naphthylacetic acid, 6-benzyladenine, aluminium sulfate, boscalid, dodine, esfenvalerate, eugenol, fenpyroximate, fluazifop-P, fluazinam, fluometuron, fluopyram, flutolanil, geraniol, malathion, penoxsulam, pinoxaden, prohexadione, proquinazid, prosulfuron, pyrethrins, pyridaben, pyrimethanil, sintofen, spiroxamine, sulphur and thymol

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (1), and in particular Article 17, first paragraph, thereof,

Whereas:

(1) Commission Directive 1999/73/EC (2) included spiroxamine in Annex I to Council Directive 91/414/EEC (3) as an active substance until 1 September 2009 and Commission Implementing Regulation (EU) No 797/2011 (4) approved that active substance until 31 December 2021.

(2) Commission Directive 2000/50/EC (5) included prohexadione, as prohexadione-calcium, in Annex I to Directive 91/414/EEC as an active substance until 1 October 2010 and Commission Implementing Regulation (EU) No 702/2011 (6) approved that active substance until 31 December 2021.

(3) Commission Directive 2000/67/EC (7) included esfenvalerate in Annex I to Directive 91/414/EEC as an active substance until 31 July 2011 and Commission Implementing Regulation (EU) 2015/2047 (8) renewed the approval of the active substance as a candidate for substitution until 31 December 2022.

(4) Commission Directive 2002/48/EC (9) included prosulfuron in Annex I to Directive 91/414/EEC as an active substance until 30 June 2011 and Commission Implementing Regulation (EU) 2017/375 (10) renewed the approval of the active substance as a candidate for substitution until 30 April 2024.

(5) Commission Directive 2006/74/EC (11) included pyrimethanil as an active substance in Annex I to Directive 91/414/EEC until 31 May 2017.

(6) Commission Directive 2008/44/EC (12) included boscalid as an active substance in Annex I to Council Directive 91/414/EEC until 31 July 2018.

(7) Commission Directive 2008/107/EC (13) included fenpyroximate as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(8) Commission Directive 2008/108/EC (14) included fluazinam and flutolanil as active substances in Annex I to Directive 91/414/EEC until 28 February 2019.

(9) Commission Directive 2008/127/EC (15) included pyrethrins as an active substance in Annex I to Directive 91/414/EEC until 31 August 2019.

(10) Commission Directive 2009/70/EC (16) included sulphur as an active substance in Annex I to Directive 91/414/EEC until 30 December 2019.

(11) Commission Directive 2010/17/EU (17) included malathion as an active substance in Annex I to Directive 91/414/EEC until 30 April 2020.

(12) Commission Directive 2010/25/EU (18) included penoxsulam and proquinazid as active substances in Annex I to Directive 91/414/EEC until 31 July 2020.

(13) Commission Directive 2010/90/EU (19) included pyridaben as an active substance in Annex I to Directive 91/414/EEC until 30 April 2021.

(14) Commission Directive 2011/1/EU (20) included 6-benzyladenine as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(15) Commission Directive 2011/9/EU (21) included dodine as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(16) Commission Directive 2011/33/EU (22) included 1-decanol as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(17) Commission Implementing Directive 2011/40/EU (23) included sintofen as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(18) Commission Implementing Directive 2011/47/EU (24) included aluminium sulfate as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(19) Commission Implementing Directive 2011/57/EU (25) included fluometuron as an active substance in Annex I to Directive 91/414/EEC until 31 May 2021.

(20) Commission Implementing Regulation (EU) No 786/2011 (26) approved the active substance 1-naphthylacetamide until 31 December 2021.

(21) Commission Implementing Regulation (EU) No 787/2011 (27) approved the active substance 1-naphthylacetic acid until 31 December 2021.

(22) Commission Implementing Regulation (EU) No 788/2011 (28) approved the active substance fluazifop-P until 31 December 2021.

(23) Commission Implementing Regulation (EU) No 546/2013 (29) approved the active substance eugenol until 30 November 2023.

(24) Commission Implementing Regulation (EU) No 568/2013 (30) approved the active substance thymol until 30 November 2023.

(25) Commission Implementing Regulation (EU) No 570/2013 (31) approved the active substance geraniol until 30 November 2023.

(26) Commission Implementing Regulation (EU) No 802/2013 (32) approved the active substance fluopyram until 31 January 2024.

(27) Commission Implementing Regulation (EU) 2016/370 (33) approved the active substance pinoxaden until 30 June 2026.

(28) The active substances 1-decanol, 6-benzyladenine, aluminium sulfate, boscalid, dodine, fenpyroximate, fluazinam, fluometuron, flutolanil, malathion, penoxsulam, proquinazid, pyrethrins, pyridaben, pyrimethanil, sintofen and sulphur were included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (34). The active substances 1-naphthylacetamide, 1-naphthylacetic acid, eugenol, fluazifop-P, fluopyram, geraniol, pinoxaden, prohexadione, spiroxamine and thymol were included in Part B, and the active substances esfenvalerate and prosulfuron were included in Part E of the Annex to that Regulation.

(29) Commission Implementing Regulation (EU) 2023/689 (35) extended the approval period of the active substance fenpyroximate until 15 June 2026, and the approval periods of the active substances malathion and pyridaben until 31 July 2026.

(30) Commission Implementing Regulation (EU) 2023/918 (36) extended the approval period of the active substance boscalid until 15 April 2026, and the approval periods of the active substances penoxsulam and proquinazid until 15 May 2026.

(31) Commission Implementing Regulation (EU) 2023/1446 (37) extended the approval period of the active substance pyrethrins until 15 June 2026.

(32) Commission Implementing Regulation (EU) 2023/1757 (38) extended the approval periods of the active substances eugenol, geraniol and thymol until 30 April 2026.

(33) Commission Implementing Regulation (EU) 2023/2592 (39) extended the approval periods of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, fluazifop-P, prohexadione, spiroxamine and esfenvalerate until 31 May 2026.

(34) Commission Implementing Regulation (EU) 2024/324 (40) extended the approval period of the active substance fluazinam until 15 April 2026, and the approval period of the active substance fluopyram until 30 June 2026.

(35) Commission Implementing Regulation (EU) 2024/1206 (41) extended the approval periods of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, dodine, fluometuron and sintofen until 15 July 2026, and the approval period of the active substance prosulfuron until 15 June 2026.

(36) Commission Implementing Regulation (EU) 2025/99 (42) extended the approval period of the active substance pyrimethanil until 30 June 2026, and the approval period of the active substance sulphur until 31 July 2026.

(37) Commission Implementing Regulation (EU) 2025/787 (43) extended the approval period of the active substance flutolanil until 15 June 2026.

(38) Applications for the respective renewals of the approval of the active substances 1-naphthylacetamide, 1-naphthylacetic acid, boscalid, esfenvalerate, eugenol, fenpyroximate, fluazifop-P, fluazinam, fluopyram, flutolanil, geraniol, malathion, penoxsulam, prohexadione, proquinazid, pyrethrins, pyridaben, pyrimethanil, spiroxamine, sulphur and thymol were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 (44).

(39) On 25 January 2019, 25 January 2019, 3 September 2015, 25 February 2020, 17 December 2020, 30 June 2016, 20 March 2019, 11 April 2016, 22 March 2021, 14 March 2016, 17 December 2020, 17 July 2017, 12 February 2020, 28 January 2019, 14 September 2017, 14 February 2017, 23 May 2018, 17 January 2014, 31 January 2019, 20 February 2017 and 17 December 2020, the rapporteur Member States, for the active substances 1-naphthylacetamide, 1-naphthylacetic acid, boscalid, esfenvalerate, eugenol, fenpyroximate, fluazifop-P, fluazinam, fluopyram, flutolanil, geraniol, malathion, penoxsulam, prohexadione, proquinazid, pyrethrins, pyridaben, pyrimethanil, spiroxamine, sulphur and thymol, respectively, informed the co-rapporteur Member States, the Commission and the European Food Safety Authority (the ‘Authority’) that they had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular the completeness and the timeliness, of each of the applications for renewal of the approval of each of those active substances and concluded that they were admissible. Those applications have been made public by the Authority pursuant to Article 5 of Implementing Regulation (EU) No 844/2012.

(40) The risk assessments pursuant to Article 11 of Implementing Regulation (EU) No 844/2012 for 1-naphthylacetamide, 1-naphthylacetic acid, esfenvalerate, fluazifop-P, pyridaben and spiroxamine have not yet been finalised by the rapporteur Member States and additional time is required to complete the remaining steps in each renewal procedure.

(41) On 14 December 2018, 2 December 2022, 8 August 2019, 21 June 2019, 26 February 2025, 3 July 2018, 2 December 2022, 17 January 2025, 25 October 2021, 26 June 2024, 14 February 2022, 30 April 2021, 31 August 2017, 28 September 2020 and 2 December 2022, the rapporteur Member States for the active substances boscalid, eugnol, fenpyroximate, fluazinam, fluopyram, flutolanil, geraniol, malathion, penoxsulam, prohexadione, proquinazid, pyrethrins, pyrimethanil, sulphur and thymol, respectively, submitted the draft renewal assessment reports to the Authority. The Authority, pursuant to Article 12 of Implementing Regulation (EU) No 844/2012, concluded that the reports for all those active substances contained all the relevant information in the agreed format, circulated them to the applicants and to the other Member States and made them available to the public for written comments. However, additional time is needed for the Authority to complete the evaluations and to finalise its conclusions for fluopyram, malathion and prohexadione, as well as for the Commission to adopt the ensuing risk management decisions.

(42) For the active substances boscalid, eugenol, fenpyroximate, fluazinam, flutolanil, geraniol, penoxsulam, proquinazid, pyrethrins, pyrimethanil, sulphur, and thymol, on 14 August 2021, 4 April 2024, 4 June 2020, 12 March 2020, 18 February 2019, 4 April 2024, 14 September 2022, 5 June 2023, 17 October 2022, 8 July 2019, 3 March 2022 and 4 April 2024, respectively, additional information for the purposes of the renewal assessment was requested by the Authority pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and was submitted by the applicants within the deadline given. However, additional time is needed for the Authority to complete the evaluations and to finalise its conclusions for boscalid, eugenol, geraniol and thymol, as well as for the Commission to adopt the ensuing risk management decisions.

(43) For the active substances fenpyroximate, fluazinam, flutolanil, proquinazid, pyrethrins and pyrimethanil, on 4 November 2021, 17 June 2021, 12 July 2019, 12 April 2024, 28 August 2023 and 16 December 2019, respectively, additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605 (45), was requested by the Authority in consultation with the Member States pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012. The additional information for fenpyroximate, fluazinam, flutolanil, proquinazid and pyrimethanil was submitted by the applicants within the deadline given, and for pyrethrins the submission is pending. The rapporteur Member States submitted the revised draft renewal assessment reports for fenpyroximate, fluazinam, flutolanil, proquinazid, pyrimethanil and flurochloridone to the Authority and the public consultations on them finished on 24 November 2024, 28 September 2024, 24 June 2022, 13 June 2025 and 12 December 2022, respectively. However, additional time is needed for the Authority to complete the evaluation and to finalise its conclusions for fenpyroximate, fluazinam and proquinazid, as well as for the Commission to adopt the ensuing risk management decision.

(44) For the active substances flutolanil, penoxsulam, pyrimethanil and sulphur, the Authority adopted its conclusions on 31 March 2023, 30 September 2024, 28 August 2024 and 21 December 2024, respectively, and communicated them to the applicants, the Member States and the Commission. The conclusion on pyrimethanil was amended by the Authority on 7 March 2025. The Commission has initiated discussions on the renewal of the approvals of those active substances in the Standing Committee on Plants, Animals, Food and Feed. Additional time is necessary for the delivery of the opinion of that Committee and for the Commission to adopt the ensuing risk management decisions.

(45) Applications for the respective renewals of the approval of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, dodine, fluometuron, prosulfuron and sintofen were initially submitted in accordance with Implementing Regulation (EU) No 844/2012. On 30 November 2018, 18 June 2018, 18 June 2018, 19 March 2019, 28 June 2018 and 15 June 2018, the rapporteur Member States, respectively, for the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, dodine, fluometuron and sintofen informed the co-rapporteur Member States, the Commission and the Authority that they had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular the completeness and the timeliness, of each of the applications for renewal of the approval of each of those active substances and concluded that they were admissible. On 27 March 2021, Commission Implementing Regulation (EU) 2020/1740 (46) became applicable to all those active substances and new applications for the respective renewal of the approvals were submitted in accordance with its provisions.

(46) Applications for the respective renewal of the approvals of the active substances pinoxaden and prosulfuron were submitted in accordance with Implementing Regulation (EU) 2020/1740.

(47) On 7 June 2022, 19 October 2021, 4 April 2022, 29 March 2023, 25 January 2022, 6 May 2024, 24 July 2023 and 4 January 2022, the rapporteur Member State for the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, dodine, fluometuron, pinoxaden, prosulfuron and sintofen, respectively, informed the co-rapporteur Member State, the Commission and the Authority that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular the completeness and the timeliness of each of the applications for renewal of the approval of each of those active substances and concluded that they were admissible. Those applications have been made public by the Authority pursuant to Article 10 of Implementing Regulation (EU) 2020/1740.

(48) The risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 for 6-benzyladenine, aluminium sulfate, fluometuron, pinoxaden, prosulfuron and sintofen have not yet been finalised by the rapporteur Member States and additional time is required to complete the remaining steps in each renewal procedure.

(49) On 7 March 2025 and 11 November 2023, the rapporteur Member States, respectively, for the active substances 1-decanol and dodine submitted the draft renewal assessment reports to the Authority. The Authority, pursuant to Article 12 of Implementing Regulation (EU) 2020/1740, is still in the process of examining whether the report for 1-decanol containes all the relevant information in the agreed format. The report for dodine has been presented for public consultation and additional information for the purposes of the assessment of the approval criteria was requested by the Authority on 22 July 2025, that was submitted by the applicants within the deadline given. However, additional time is needed for the Authority to complete the evaluation and to finalise its conclusions for 1-decanol and dodine, as well as for the Commission to adopt the ensuing risk management decision.

(50) It is therefore likely for all of the active substances covered by this Regulation that no decision on the renewal of the approval can be taken before the expiry of their respective approval periods, between 15 April and 31 July 2026.

(51) Furthermore, on the basis of the information available at the moment of adoption of this Regulation, including that provided by the rapporteur Member States and the Authority, the Commission considers that the reasons for the delays in each of these renewal procedures are beyond the control of the respective applicants.

(52) Therefore, taking into account the temporary and exceptional nature of the mechanism for the extension of approvals, the approval periods of those active substances should be extended for the period assessed as necessary, in each specific case and on the basis of the information available at the moment of adoption of this Regulation, to finalise the respective procedures on the renewal of the approvals.

(53) For the active substances 1-naphthylacetamide, 1-naphthylacetic acid, 6-benzyladenine, aluminium sulfate, esfenvalerate, fluazifop-P, fluometuron, pinoxaden, prosulfuron, pyridaben, sintofen and spiroxamine, the risk assessment has not been finalised yet by the rapporteur Member State. Taking into account the subsequent steps to be completed in each renewal procedure, the duration of the extension of the approval periods of these active substances should be set at 42 months.